{"filing":{"accession_number":"0001193125-26-341385","cik":"0001680581","ticker":"FULC","company_name":"Fulcrum Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-07","primary_document":"fulc-20260807.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1680581/000119312526341385/fulc-20260807.htm"},"events":[{"id":26425,"run_id":24017,"accession_number":"0001193125-26-341385","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"summary":"The disclosure centers on the Board's appointment of Alan Musso as principal accounting officer effective August 7, 2026, following Greg Tourangeau's departure from that role. While both a departure and an appointment occur, the principal action disclosed is the appointment of Musso to the principal accounting officer position. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting oversight.","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27545,"accession_number":"0001193125-26-341385","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the Board's appointment of Alan Musso as principal accounting officer effective August 7, 2026, following Greg Tourangeau's departure from that role. While both a departure and an appointment occur, the principal action disclosed is the appointment of Musso to the principal accounting officer position. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:45:36.780630+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27545,"accession_number":"0001193125-26-341385","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The disclosure centers on the Board's appointment of Alan Musso as principal accounting officer effective August 7, 2026, following Greg Tourangeau's departure from that role. While both a departure and an appointment occur, the principal action disclosed is the appointment of Musso to the principal accounting officer position. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T12:45:36.780630+00:00","company_name":"Fulcrum Therapeutics, Inc.","ticker":"FULC","filing_date":"2026-08-10"}]}